Company Monitoring Page for Alkermes

latest headlines for company on cafepharma

Drug rejections rise as Covid-19 bites
EP Vantage
Wed, 11/18/20 - 01:20 pm
Tags:
COVID-19, drug approvals, Alkermes, ALKS 3831, pandemic, regulatory inspections
Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front
Endpoints
Tue, 11/17/20 - 10:48 am
Tags:
Alkermes, ALKS-3831, FDA, CRL
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
Xconomy
Sat, 10/10/20 - 11:36 pm
Tags:
Alkermes, FDA, advisory panels, ALKS 3831, schizophrenia, bipolar disorder
FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug
BioSpace
Thu, 10/8/20 - 11:21 pm
Tags:
Alkermes, FDA, schizophrenia, opioids, ALKS 3831
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
Tags:
FDA, drug approvals, vaccines, Pfizer, Moderna Therapeutics, COVID-19, Regeneron, EB3, ebola virus, Alkermes, ALKS-3831, schizophrenia, bipolar disorder, Bristol-Myers Squibb, liso-cel, non-Hodgkin lymphoma, roxadustat, FibroGen, chronic kidney disease
Esmo 2020 – can Alkermes succeed where Nektar failed?
EP Vantage
Wed, 09/23/20 - 10:33 am
Tags:
Alkermes, ESMO, ALKS 4230, melanoma
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Fri, 09/18/20 - 11:09 am
Tags:
Alkermes, immuno-oncology, ESMO, ALKS 4230, Keytruda
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions
Fierce Biotech
Fri, 08/21/20 - 11:36 pm
Tags:
Alkermes, schizophrenia, bipolar disorder, FDA, ALKS 3831
Top Biopharma M&As in 2019
BioSpace
Fri, 01/3/20 - 10:06 am
Tags:
M&A, Bristol-Myers Squibb, Celgene, AbbVie, Allergan, Roche, Spark Therapeutics, Novartis, The Medicines Company, Alkermes, Rodin Therapeutics, Sumitomo Dainippon, Roivant
FDA slaps down Alkermes for misleading Vivitrol ads — don't forget vulnerability to opioid overdose
Endpoints
Wed, 12/11/19 - 10:24 pm
Tags:
Alkermes, drug ads, Vivitrol
Alkermes To Acquire Rodin Therapeutics
NASDAQ
Mon, 11/18/19 - 09:58 am
Tags:
Alkermes, Rodin Therapeutics, M&A, CNS
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Endpoints
Wed, 10/30/19 - 10:13 am
Tags:
Biogen, Alkermes, FDA, multiple sclerosis, MS, Vumerity
Alkermes to lay off 160 in cost-cutting restructure
Biopharma Dive
Wed, 10/23/19 - 02:57 pm
Tags:
Alkermes, restructuring, layoffs
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
Endpoints
Tue, 07/30/19 - 11:29 am
Tags:
Biogen, Alkermes, MS, multiple sclerosis, Vumerity, clinical trials
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
Sun, 07/28/19 - 11:48 pm
Tags:
biotech, earnings, Immunic, Alkermes, Conatus, Aevi Genomic, Tricida, Curis, Ultragenyx, Leap Therapeutics, Cidara Therapeutics, Akcea, Spark Therapeutics, Eli Lilly, AnaptysBio, clinical trials
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Tags:
Biogen, MS, multiple sclerosis, Tecfidera, ALKS 8700, Vumerity, Alkermes
Here's Why Shares of Alkermes Sank Today
Motley Fool
Thu, 04/25/19 - 06:50 pm
Tags:
Alkermes, earnings
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Mon, 02/25/19 - 12:24 pm
Tags:
Alkermes, Biogen, diroximel fumarate, MS, multiple sclerosis
Mon, 02/25/19 - 10:16 am
Tags:
Alkermes, Biogen, diroximel fumarate
Alkermes Breaks $1 Billion
Motley Fool
Tue, 02/19/19 - 12:18 pm
Tags:
Alkermes, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.